Biodesix IDs Proteomic Signature for Predicting Response to GlobeImmune Pancreatic Cancer Therapy | GenomeWeb

Biodesix this week presented data indicating that a proteomic signature identified using the company's ProTS mass spec-based system can identify pancreatic cancer patients likely to respond to treatment with GlobeImmune's GI-4000 therapy.

Presented at the European Society of Medical Oncology's 14th World Congress on Gastrointestinal Cancer, the findings emerged from a collaboration between the two companies focused on developing a companion diagnostic to support GI-4000's clinical development and, ultimately, its clinical implementation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.